Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L.
Albrecht LJ, et al. Among authors: grover p.
Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1.
Eur J Cancer. 2024.
PMID: 38484692
Free article.